Overview: HBV Genotype TestIntroduction: The HBV Genotype Test identifies hepatitis B virus genotypes to guide treatment for hepatitis B, causing liver damage or jaundice, helping optimize antiviral therapy. Affecting 1 in 1,000 people globally, hepatitis B poses diagnostic challenges due to chronic progression. Following 2023 American Association for the Study of Liver Diseases (AASLD) guidelines, it uses PCR/sequencing for high accuracy, supporting virology screening. This test is vital for diagnosis, treatment planning, and improving outcomes in hepatology.
Other Names: Hepatitis B Genotyping Test, HBV Strain Assay.
FDA Status: Laboratory-developed test (LDT), meeting virology standards for diagnostic reliability.
Historical Milestone: HBV genotyping began in the 1980s with research by Okamoto, who identified genotypes. PCR/sequencing advancements in the 2000s by Roche improved detection, surpassing earlier serology methods.
Purpose: Identifies HBV genotypes to optimize antiviral therapy, guides monitoring, and evaluates patients with liver issues, aiming to prevent cirrhosis.
Test Parameters: HBV genotype
Pretest Condition: No special preparation required. Collect whole blood or plasma. Report history of liver disease.
Specimen: Whole Blood (EDTA, 3-5 mL), Plasma (EDTA, 2-4 mL); 2 mL serum in SST. Transport in a biohazard container.
Sample Stability at Room Temperature: 6 hours
Sample Stability at Refrigeration: 1 week
Sample Stability at Frozen: 1 month
Medical History: Document liver damage or jaundice. Include current medications or vaccination history.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., hepatocellular carcinoma), and sample collection risks.
Procedural Considerations: Uses PCR/sequencing to identify genotypes, requiring labs with thermal cyclers. Results available in 3-5 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample degradation or contamination can affect results. Medications may not affect results but require correlation.
Clinical Significance: Specific genotype guides therapy, improving outcomes. Early treatment might prevent progression, while untreated cases lead to liver failure. Negative results may require serology.
Specialist Consultation: Consult a hepatologist for interpretation.
Additional Supporting Tests: HBV DNA test, liver function test, or biopsy to confirm diagnosis.
Test Limitations: Specific to HBV; correlation with viral load needed. False negatives possible with low viral levels.
References: AASLD Guidelines, 2023; Journal of Hepatology, Okamoto H, 2022.
